The majority of men with prostate cancer are aged≥ 65 years. Men, as they age, are more
likely to suffer from impaired physical function. The standard treatment for recurrent prostate …

OBJECTIVE: To determine the baseline prevalence of cognitive impairment in older men
treated with ADT and to assess changes in cognitive performance over time. METHODS …

BACKGROUND. Impairments in geriatric domains adversely affect health outcomes of the
elderly. The Comprehensive Geriatric Assessment (CGA) is a key component of the …

Prostate cancer is the most common malignancy in older men. With the aging of the
population, the number of older men with prostate cancer will grow rapidly. Androgen …

OBJECTIVES: Men experience a decrease in lean muscle mass and strength during the first
year of androgen deprivation therapy (ADT). The prevalence of falls and physical and …

BACKGROUND Angiogenesis contributes to the progression of urothelial carcinoma (UC).
In the current study, the authors investigated the role of maintenance sunitinib in patients …

OBJECTIVES: To test the hypothesis that early androgen deprivation therapy (ADT) has no
proven survival advantage in older men with biochemical recurrence (BCR) of prostate …

OBJECTIVE To report a randomized, placebo‐controlled study of treatment with zoledronic
acid every 3 months in patients with hormone‐sensitive prostate cancer, both with and …

Purpose Androgen deprivation therapy (ADT) is first-line therapy for patients with prostate
cancer (PCA) who experience biochemical recurrence (BCR). However, the optimal timing …

Pancreatic cancer is refractory to most chemotherapy. For many years, the only active agent
for this disease was gemcitabine, which has very modest activity. Two new regimens …